References
- SchnellOCappuccioFGenoveseSStandlEValensiPCerielloAType 1 diabetes and cardiovascular diseaseCardiovasc Diabetol20131215624165454
- BlankenbergSRupprechtHJPoirierOPlasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular diseaseCirculation2003107121579158512668489
- ShiauMYTsaiSTTsaiKJHaungMLHsuYTChangYHIncreased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitusMt Sinai J Med20067371024102817195891
- JacqueminetSBen AbdesselamOChapmanMJElevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathyClin Chim Acta20063671–210310716426593
- SetiantoBYAchmadAFPurnomoLBSerum matrix metalloproteinase-9 levels in acute coronary syndrome patients with and without hyperglycemiaActa Med Indones2014462838925053679
- UemuraSMatsushitaHLiWDiabetes mellitus enhances vascular matrix metalloproteinase activity role of oxidative stressCirc Res200188121291129811420306
- TölleSGLP-1-analoga in der therapie des diabetes mellitus typ 1 [GLP-1 analogues in treatment of type 1 diabetes mellitus]Dtsch Med Wochenschr20141394221232126 German25289919
- CerielloANovialsAOrtegaEGlucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetesDiabetes Care20133682346235023564922